Authors: Tetef, ML Synold, TW Chow, W Leong, L Margolin, K Morgan, R Raschko, J Shibata, S Somlo, G Yen, Y Groshen, S Johnson, K Lenz, HJ Gandara, D Doroshow, JH

Citation: Ml. Tetef et al., Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies, CLIN CANC R, 7(6), 2001, pp. 1569-1576

Authors: Somlo, G Doroshow, JH Synold, T Longmate, J Reardon, D Chow, W Forman, SJ Leong, LA Margolin, KA Morgan, RJ Raschko, JW Shibata, SI Tetef, ML Yen, Y Kogut, N Schriber, J Alvarnas, J

Citation: G. Somlo et al., High-dose paclitaxel in combination with doxorubicin, cyclophosphamide andperipheral blood progenitor cell rescue in patients with high-risk primaryand responding metastatic breast carcinoma: toxicity profile, relationshipto paclitaxel pharmacokinetics and short-term outcome, BR J CANC, 84(12), 2001, pp. 1591-1598

Authors: Raschko, JW Synold, TW Chow, W Coluzzi, P Hamasaki, V Leong, LA Margolin, KA Morgan, RJ Shibata, SI Somlo, G Tetef, ML Yen, Y ter Veer, A Doroshow, JH

Citation: Jw. Raschko et al., A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A, CANC CHEMOT, 46(5), 2000, pp. 403-410

Authors: Tetef, ML Margolin, KA Doroshow, JH Akman, S Leong, LA Morgan, RJ Raschko, JW Slatkin, N Somlo, G Longmate, JA Carroll, MI Newman, EM

Citation: Ml. Tetef et al., Pharmacokinetics and toxicity of high-dose intravenous methotrexate in thetreatment of leptomeningeal carcinomatosis, CANC CHEMOT, 46(1), 2000, pp. 19-26